UK5 Day2 France Presentation LONDRES CCO

Information about UK5 Day2 France Presentation LONDRES CCO

Published on May 2, 2008

Author: Lassie

Source: authorstream.com

Content

Slide1:  Defining a High Performance Cancer System: The French System Christine Lepage Laurent Borella Laurent Cals London 24 & 25 June 2007 Slide2:  1 The INCa’s policy to improve access to innovative cancer drugs Slide3:  One of the goals of the Cancer Plan: equal access to quality and innovation  a model = the drug Rise in global costs  challenge = control costs through best use Tous médicaments hôpital (AFSSAPS) Promoting equal access and best use of innovative drugs in France Slide4:  Equal access, guaranteed funding, including off-label use New systems of funding in 2004 for a specific list of expensive and innovative drugs  ”medicines“ decree of 24 August 2005 : General commitments: quality procedures, multidisciplinary consultations, respect of guidelines, obligatory participation in the Observatories Specific commitments for innovative drugs: compliance with the Marketing Authorisation or with best use guidelines defined by the INCa exceptionally, the prescriber can justify a prescription by making reference to studies from learned societies or from the international scientific literature Promoting equal access and best use of innovative drugs in France Slide5:  Best use guidelines The INCa, in collaboration with the AFSSAPS and the HAS, defines the protocols of off-label prescription: According to the scientific context at the time of writing Temporary and progressive according to available data and requests for, or changes to, Marketing Authorisations by the pharmaceutical laboratories Considering the possible directions to take in terms of clinical research or therapeutic strategy. Promoting equal access and best use of innovative drugs in France Slide6:  Knowledge, anticipation Updated databases of drug use:  regional and national  qualitative and quantitative Compare this information with epidemiological cancer data and with actions undertaken in the framework of the Cancer Plan Describe and quantify the penetration of innovation Impact of measures taken at the national, regional or local level concerning drugs Cost of treatment and its progression Drug Observatories: goals Slide7:  Regional and inter-regional observatories: 22 at the end of 2006 Slide8:  2 The cancer treatment authorisation procedure in France Slide9:  The Cancer Plan’s solution for access to cancer treatment Cancer treatments will not be concentrated in specialised centres but will be made available in all health establishments for part, or all, of the therapy However, the establishments will not be authorised to undertake cancer treatment unless they respect ”quality criteria“ and have a ”minimum activity threshold“ What will change … ”quality“:  What will change … ”quality“ All establishments are required to adhere to the obligatory quality conditions and the activity thresholds within a period of two years. Obligatory (INCa) : Diagnostic disclosure Multidisciplinary consultation Personalised care programme Adherence to guidelines Access to supportive care Access to clinical trials And participation in a network recognised by the INCa What will change … ”thresholds“, ”recommendations“:  What will change … ”thresholds“, ”recommendations“ The annual minimum activity thresholds have been established for different treatments, by organ or pathology where appropriate Opposable quality criteria (consent) and recommendations on the quality of each treatment, as well as quality assurance indicators, have been defined by the Institut National du Cancer The threshold decree:  The threshold decree Minimum annual activity thresholds which must be respected by health establishments: For external radiotherapy, per site with at least two machines: at least 600 patients per year For chemotherapy at least: 80 patients per year or 50 patients for outpatient treatment A minimum annual activity per cancer and per establishment for surgery:  A minimum annual activity per cancer and per establishment for surgery Breast cancers 30 per year Digestive cancers 30 per year Urological cancers 30 per year Thoracic cancers 30 per year Gynaecological cancers 20 per year ENT cancers 30 per year Slide15:  Adéquation niveau/options 2003 96,5% 92% 93% 3% 6% 6% 0,5% 2% 1% 78,5% 14,5% 65,7% 78% 14% 31,3% Slide16:  3 Breast Cancer Screening The most frequent cancer in women :  The most frequent cancer in women The number of new cases has almost doubled over the last 20 years 42,000 new cases estimated in France in 2000 Annual average rate of progression: +2.4% per year Main cause of death by cancer in women (11,000 deaths in 2003) Organised breast cancer screening:  Organised breast cancer screening Organised screening by mammography started between 1989 and 1991 National roll-out in March 2004 Aimed at women aged from 50 to 74 Examination proposed every 2 years Each mammography is systematically subject to a second expert reading by a radiologist The examination is free Coordinated by a local management structure Organised breast cancer screening:  Organised breast cancer screening Technical aspects: A mammography (2 per breast frontal and oblique) and a clinical examination Mammography done in private and public radiology practices 1st reading: the radiologists must have read at least 500 mammographies per year. 2nd reading: the radiologists must read at least 1500 radiographies per year Adherence to strict criteria Strict safety standards for equipment Regular checks by the AFSSAPS (French drug agency) Plan: to progressively change over to digital mammography Evaluation of the individual and organised screening programme:  Evaluation of the individual and organised screening programme Two systems of screening in France: Organised screening and individual screening Rate of screening: 72% The participation rate for women rose from 33.6% in 2003 to 40.2% in 2004 and 45.1% in the target population in 2005 A cancer rate of 6.6 for 1000 screened women. Among the screened cancers, 6.7% were detected by the second reader The cost of organising cancer screening was estimated at 70M€ in 2006 Slide21:  4 Colorectal Cancer Screening Colorectal cancer:  Colorectal cancer Colorectal cancer is frequent in Western countries Groups at risk are now starting to be identified as well as the characteristics of the adenoma-cancer sequence, permitting development of a screening strategy. A large consumption of vegetables reduces risk, whilst a sedentary lifestyle and high calorie intake increases risk of developing the cancer. It is now well established, in countries with a high risk, that the organisation of mass screening, based on a test for occult bleeding in the faeces, leads to a reduction in death by colorectal cancer. Colorectal cancer:  Colorectal cancer 3rd most frequent cancer in France 37,000 new cases estimated in France in 2000 Annual rate of progression: + 0.99% in men and + 0.83% in women 16,000 deaths in 2003 Colorectal cancer screening:  Colorectal cancer screening Progressive implementation of a national policy (planned for end of 2007) Organised screening every two years 50-74 years (age range recommended by the European Union) Test: look for occult bleeding in the faeces Choice of a limited number of laboratories Only 1 sort of test used Managed by the local management structures People at high or very high risk are subject to different procedures with a coloscopy done straight away Participation rate 42% (in 19 counties) Colorectal cancer screening Pilot programme in 4 counties:  Colorectal cancer screening Pilot programme in 4 counties First results in pilot programmes (Côte d’Or, Haut-Rhin, Ile-et-Vilaine, Saône-et-Loire) 621,449 people aged from 50 to 74 invited  324,389 tests done (52.2%)  9427 positive (2.9%)  7927 coloscopies (84.3%)   763 cancers 2623 adenoma (2.3 for 1000 screened) (8 for 1000 screened) Slide26:  52 avenue André Morizet ● 92513 Boulogne-Billancourt Cedex ● France Tél. +33 (0) 1 41 10 50 00 ● Fax +33 (0) 1 41 10 50 20 www.e-cancer.fr

Related presentations


Other presentations created by Lassie

Presentation Accenture
12. 03. 2008
0 views

Presentation Accenture

Taxation
19. 10. 2007
0 views

Taxation

population
21. 10. 2007
0 views

population

19 sethusamudram ppt
30. 09. 2007
0 views

19 sethusamudram ppt

sample seminar
02. 05. 2008
0 views

sample seminar

Oral Radiology
02. 05. 2008
0 views

Oral Radiology

Rainfall
07. 04. 2008
0 views

Rainfall

Andrew
19. 02. 2008
0 views

Andrew

campaigns and elections
07. 01. 2008
0 views

campaigns and elections

Emergency Planning
03. 10. 2007
0 views

Emergency Planning

stjerna 060307
09. 10. 2007
0 views

stjerna 060307

ElectiveWkshpGoalSet
10. 10. 2007
0 views

ElectiveWkshpGoalSet

p5animals
12. 10. 2007
0 views

p5animals

RT
12. 10. 2007
0 views

RT

pinarsut
13. 10. 2007
0 views

pinarsut

Lecture19 Ch19 111405
15. 10. 2007
0 views

Lecture19 Ch19 111405

Poster APS summary
16. 10. 2007
0 views

Poster APS summary

david ingleby
17. 10. 2007
0 views

david ingleby

Ole Lund
23. 10. 2007
0 views

Ole Lund

acmmm02
24. 10. 2007
0 views

acmmm02

rebecca
11. 12. 2007
0 views

rebecca

HHH Scandale
17. 10. 2007
0 views

HHH Scandale

1 WMO
19. 10. 2007
0 views

1 WMO

Great Britain
02. 11. 2007
0 views

Great Britain

ENYA
02. 11. 2007
0 views

ENYA

5AlpaShah
06. 11. 2007
0 views

5AlpaShah

Rectoria Panama 2006
25. 10. 2007
0 views

Rectoria Panama 2006

L10a 4345 Sp02
07. 11. 2007
0 views

L10a 4345 Sp02

Shahriar
15. 11. 2007
0 views

Shahriar

lakshmi wireless
15. 11. 2007
0 views

lakshmi wireless

CONTEMPORARY DANCE LESSONS
23. 11. 2007
0 views

CONTEMPORARY DANCE LESSONS

price iso 15926 as owl
07. 11. 2007
0 views

price iso 15926 as owl

acute 060718 neuroemergencies
23. 10. 2007
0 views

acute 060718 neuroemergencies

The Olmec
21. 11. 2007
0 views

The Olmec

wetlands inventory
03. 01. 2008
0 views

wetlands inventory

plainChairdesign
04. 01. 2008
0 views

plainChairdesign

Polymorphic Robotics at ISI
07. 01. 2008
0 views

Polymorphic Robotics at ISI

t Campout with Foodborne Illness
07. 01. 2008
0 views

t Campout with Foodborne Illness

poly web cast
15. 10. 2007
0 views

poly web cast

MTAC 11 06v1 03georgewright
06. 11. 2007
0 views

MTAC 11 06v1 03georgewright

awmapres041905
31. 10. 2007
0 views

awmapres041905

Insecta
23. 10. 2007
0 views

Insecta

ficci wo pictures
29. 12. 2007
0 views

ficci wo pictures

Modelos de control Ley 24156
22. 10. 2007
0 views

Modelos de control Ley 24156

severe wx
07. 10. 2007
0 views

severe wx

Egypt presentation salem 2nd
21. 10. 2007
0 views

Egypt presentation salem 2nd

nursinghome
29. 11. 2007
0 views

nursinghome

IMechE 19th May
15. 10. 2007
0 views

IMechE 19th May

EGEE Summer School 2007
17. 10. 2007
0 views

EGEE Summer School 2007

Carolyn
31. 12. 2007
0 views

Carolyn

4 Systematic chemistry web cec
16. 02. 2008
0 views

4 Systematic chemistry web cec

hsearch
20. 11. 2007
0 views

hsearch

kimkidu
24. 02. 2008
0 views

kimkidu

IntroMiscConcl
27. 02. 2008
0 views

IntroMiscConcl

dutchhistoryfordummi es
27. 02. 2008
0 views

dutchhistoryfordummi es

hansen2
29. 10. 2007
0 views

hansen2

sciencenews
29. 09. 2007
0 views

sciencenews

Running a vegetarian campaign
04. 03. 2008
0 views

Running a vegetarian campaign

D3 NomuraResearch
25. 03. 2008
0 views

D3 NomuraResearch

presentationkpimchan ThaiAirways
30. 03. 2008
0 views

presentationkpimchan ThaiAirways

ch19 Kreitner 2004 6e OB
08. 04. 2008
0 views

ch19 Kreitner 2004 6e OB

indiapres110606
14. 04. 2008
0 views

indiapres110606

MMM CEO
18. 04. 2008
0 views

MMM CEO

ch26 hedgingrisk
16. 04. 2008
0 views

ch26 hedgingrisk

myCH14
07. 05. 2008
0 views

myCH14

CROSSGRID VO SEC KD
08. 05. 2008
0 views

CROSSGRID VO SEC KD

Prescribed Fire at UNF
02. 01. 2008
0 views

Prescribed Fire at UNF

md apr quality82604 mtan
30. 04. 2008
0 views

md apr quality82604 mtan

bowles
01. 05. 2008
0 views

bowles

PSRS partI
02. 05. 2008
0 views

PSRS partI

pres1
02. 05. 2008
0 views

pres1

Waittimes presentation e
02. 05. 2008
0 views

Waittimes presentation e

ae8 eman over
26. 02. 2008
0 views

ae8 eman over

CH 9
04. 01. 2008
0 views

CH 9

Horton ALA Moving Mountains
29. 02. 2008
0 views

Horton ALA Moving Mountains

remsim
01. 11. 2007
0 views

remsim

CERLS
16. 10. 2007
0 views

CERLS

forum creativite5
23. 10. 2007
0 views

forum creativite5

Ceanothus
14. 12. 2007
0 views

Ceanothus

Pollard
24. 10. 2007
0 views

Pollard

Typology 7mfamelev
02. 11. 2007
0 views

Typology 7mfamelev

ST3
24. 10. 2007
0 views

ST3

UNITROL Service Nov2006 Aend A
19. 10. 2007
0 views

UNITROL Service Nov2006 Aend A

energetech
17. 04. 2008
0 views

energetech

Presentaton
23. 10. 2007
0 views

Presentaton

LTCOPhistoryandresp
03. 10. 2007
0 views

LTCOPhistoryandresp

schmerge experimental results
21. 11. 2007
0 views

schmerge experimental results

martemiyanov
27. 09. 2007
0 views

martemiyanov

Lecture9 JF
16. 10. 2007
0 views

Lecture9 JF

helen meeks
02. 10. 2007
0 views

helen meeks

11 Gatorpops
17. 12. 2007
0 views

11 Gatorpops

Mol gen 9910
16. 10. 2007
0 views

Mol gen 9910